The Current Treatments Of Pulmonary Arterial Hypertension

G. Butrous
{"title":"The Current Treatments Of Pulmonary Arterial Hypertension","authors":"G. Butrous","doi":"10.26577/IAM.2020.V1.I1.02","DOIUrl":null,"url":null,"abstract":"Pulmonary hypertension is a debilitating chronic disease. In the last 20 years, there has been impressive progress in the treatment strategy of pulmonary arterial hypertension. This led to a significant increase in the awareness and improvement in the clinical outcome, though there was no substantial improvement in the rate of mortality. This review summarizes the current state of the art of the treatment of pulmonary arterial hypertension, including the three main categories of pulmonary hypertension specific medication which were introduced in the last 20 years. Mainly drugs that restore prostaglandins function of the endothelial cells, drugs that restore Cyclic GMP in the endothelial cells and various forms of medication that inhibit Endothelin receptors. The current strategy to treat patients with pulmonary arterial hypertension is to initiate drug therapy as early as possible and to adopt combinational therapy using two or more classes of drugs simultaneously. There are current efforts to introduce future medication that can be more specific to a phenotype of pulmonary hypertension.","PeriodicalId":34543,"journal":{"name":"Interdisciplinary Approaches to Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary Approaches to Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26577/IAM.2020.V1.I1.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pulmonary hypertension is a debilitating chronic disease. In the last 20 years, there has been impressive progress in the treatment strategy of pulmonary arterial hypertension. This led to a significant increase in the awareness and improvement in the clinical outcome, though there was no substantial improvement in the rate of mortality. This review summarizes the current state of the art of the treatment of pulmonary arterial hypertension, including the three main categories of pulmonary hypertension specific medication which were introduced in the last 20 years. Mainly drugs that restore prostaglandins function of the endothelial cells, drugs that restore Cyclic GMP in the endothelial cells and various forms of medication that inhibit Endothelin receptors. The current strategy to treat patients with pulmonary arterial hypertension is to initiate drug therapy as early as possible and to adopt combinational therapy using two or more classes of drugs simultaneously. There are current efforts to introduce future medication that can be more specific to a phenotype of pulmonary hypertension.
肺动脉高压的治疗现状
肺动脉高压是一种使人衰弱的慢性疾病。在过去的20年里,肺动脉高压的治疗策略取得了令人印象深刻的进展。这大大提高了人们的认识,改善了临床结果,尽管死亡率没有实质性的改善。本文综述了肺动脉高压的治疗现状,包括近20年来推出的肺动脉高压特异性药物的三大类。主要是恢复内皮细胞前列腺素功能的药物,恢复内皮细胞环GMP的药物,以及各种形式的抑制内皮素受体的药物。目前治疗肺动脉高压患者的策略是尽早开始药物治疗,并采用两类或两类以上药物同时联合治疗。目前正在努力引入未来的药物,可以更具体地针对肺动脉高压的表型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
12
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信